Department of Molecular and Cellular Physiology, Stanford University, Stanford, CA 94305.
Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA 94305.
Proc Natl Acad Sci U S A. 2022 Apr 19;119(16):e2119467119. doi: 10.1073/pnas.2119467119. Epub 2022 Apr 1.
Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) challenge currently available COVID-19 vaccines and monoclonal antibody therapies due to structural and dynamic changes of the viral spike glycoprotein (S). The heptad repeat 1 (HR1) and heptad repeat 2 (HR2) domains of S drive virus–host membrane fusion by assembly into a six-helix bundle, resulting in delivery of viral RNA into the host cell. We surveyed mutations of currently reported SARS-CoV-2 variants and selected eight mutations, including Q954H, N969K, and L981F from the Omicron variant, in the postfusion HR1HR2 bundle for functional and structural studies. We designed a molecular scaffold to determine cryogenic electron microscopy (cryo-EM) structures of HR1HR2 at 2.2–3.8 Å resolution by linking the trimeric N termini of four HR1 fragments to four trimeric C termini of the Dps4 dodecamer from Nostoc punctiforme. This molecular scaffold enables efficient sample preparation and structure determination of the HR1HR2 bundle and its mutants by single-particle cryo-EM. Our structure of the wild-type HR1HR2 bundle resolves uncertainties in previously determined structures. The mutant structures reveal side-chain positions of the mutations and their primarily local effects on the interactions between HR1 and HR2. These mutations do not alter the global architecture of the postfusion HR1HR2 bundle, suggesting that the interfaces between HR1 and HR2 are good targets for developing antiviral inhibitors that should be efficacious against all known variants of SARS-CoV-2 to date. We also note that this work paves the way for similar studies in more distantly related viruses.
严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的变体由于病毒刺突糖蛋白 (S) 的结构和动态变化,对目前可用的 COVID-19 疫苗和单克隆抗体疗法构成挑战。S 中的七肽重复 1 (HR1) 和七肽重复 2 (HR2) 结构域通过组装成六螺旋束驱动病毒-宿主膜融合,从而将病毒 RNA 递送到宿主细胞中。我们调查了目前报道的 SARS-CoV-2 变体的突变,并选择了来自奥密克戎变体的 8 个突变,包括 Q954H、N969K 和 L981F,用于融合后 HR1HR2 束的功能和结构研究。我们设计了一种分子支架,通过将四个 HR1 片段的三聚体 N 末端连接到来自 Nostoc punctiforme 的 Dps4 十二聚体的四个三聚体 C 末端,来确定 HR1HR2 在 2.2-3.8 Å分辨率下的低温电子显微镜 (cryo-EM) 结构。这种分子支架通过单颗粒 cryo-EM 实现了 HR1HR2 束及其突变体的高效样品制备和结构测定。我们野生型 HR1HR2 束的结构解决了以前确定的结构中的不确定性。突变体结构揭示了突变的侧链位置及其对 HR1 和 HR2 之间相互作用的主要局部影响。这些突变不会改变融合后 HR1HR2 束的整体结构,这表明 HR1 和 HR2 之间的界面是开发抗病毒抑制剂的良好靶点,这些抑制剂应该对迄今为止所有已知的 SARS-CoV-2 变体有效。我们还注意到,这项工作为在更远缘相关的病毒中进行类似的研究铺平了道路。